Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162760 · ClinicalTrials.gov registry record · Phase 2
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00162760: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00162760 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00162760, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this study is to determine whether thalidomide can stop the progression of fibrosis in IPF. The primary objective of this study is to determine the safety, feasibility and efficacy of 400 mg of thalidomide administered daily for one year in patients with idiopathic pulmonary fibrosis (IPF) who have failed or are not candidates for treatment with corticosteroids and/or cytotoxic drugs. The study population will consist of patients with biopsy-proven moderate to severe IPF who have failed or are not candidates for standard therapy with corticosteroids and/or cytotoxic drugs.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162760
The ClinicalTrials.gov registry entry for NCT00162760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00162760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162760 about?
NCT00162760 is a clinical study titled "Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide". The goal of this study is to determine whether thalidomide can stop the progression of fibrosis in IPF. The primary objective of this study is to determine the safety, feasibility and efficacy of 400 mg of thalidomide administered daily for one year in patients with idiopathic pulmonary fibrosis (I...
What is the current status of trial NCT00162760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2003-10. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00162760?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00162760?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.